Hepatic space-occupying lesions encompass a spectrum of benign and malignant diseases, including HCC, ICC, cHCC-CCA, liver metastases, hemangiomas, FNH, HCA, inflammatory and infectious lesions
Conditions
Interventions
Sponsors
Zhongshan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >= 18 years, any gender; 2. Diagnosed with hepatic space-occupying lesions through pathology, a combination of clinical and imaging evaluation, multidisciplinary discussion, or standard follow-up, including HCC, ICC, cHCC-CCA, liver metastases, hemangioma, FNH, HCA, cysts, focal fatty changes, liver abscess, inflammatory pseudotumor, regenerative nodules, or atypical hyperplastic nodules, etc.; 3. Has undergone at least one liver-related imaging examination (CT, MRI, ultrasound, contrast-enhanced ultrasound, PET/CT, etc.) at our hospital, and the imaging data quality is sufficient for diagnosis, treatment evaluation, differential diagnosis, or feature extraction; 4. Has available baseline clinical data, lab results, imaging data, treatment information, pathology reports, biological behavior information, any genetic/molecular test results obtained during routine care (if available), or follow-up data; 5. Retrospective cohorts must have traceable medical records or follow-up information; prospective cohorts require informed consent from the patient or legal representative and willingness to follow routine follow-up procedures; 6. For patients with multiple visits or multiple imaging exams, the inclusion time point will be determined by a predefined index date and study purpose to avoid bias from duplicate entries.
Exclusion criteria
Exclusion criteria: 1. Patients with unconfirmed final diagnosis or lesions not belonging to the predefined diagnostic categories of focal liver lesions. 2. Patients complicated with other active primary malignant tumors where the origin of hepatic lesions, diagnostic category or primary study endpoints cannot be clearly identified. 3. Severe missing of key clinical, imaging, pathological or follow-up data that prevents the determination of primary study endpoints or core covariates. Isolated missing genetic/molecular test results shall not serve as an exclusion criterion, yet such cases will be excluded from analyses involving genetic features. 4. Imaging data failing to meet analytical quality requirements, such as severe motion artifacts, incomplete scan coverage, missing key sequences, or unlocalizable lesions. 5. Patients in the prospective cohort who decline study participation or withdraw informed consent, or cases where the investigator judges continued enrollment may compromise the subjects’ rights and interests or the quality of research data.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Sensitivity;Specificity;Area Under the Receiver Operating Characteristic Curve; | — |
Countries
China
Contacts
Public ContactLiu Liheng
Zhongshan Hospital, Fudan University
Outcome results
None listed